Revocation of Office of Generic Drug's interim policy statement on inactive ingredients.  Food and Drug Administration, HHS.  Notice.
The Food and Drug Administration (FDA) is revoking an interim policy statement on inactive ingredients in parenteral, ophthalmic, otic, and topical generic drug products (Interim Inactive Ingredient Policy). These generic drug products are the subjects of abbreviated new drug applications (ANDA's).  The Interim Inactive Ingredient Policy was issued as a memorandum from the Acting Director of the Center for Drug Evaluation and Research's (CDER's) Office of Generic Drugs, FDA, to CDER's Associate Director for Science and Medical Affairs, FDA. FDA is taking this action because the Interim Inactive Ingredient Policy no longer represents current agency policy.
D016568:Drugs, Generic; D005079:Excipients / Q000493:pharmacokinetics; D017408:Guidelines as Topic; D006291:Health Policy; D006801:Humans
D016568:Drugs, Generic; D005079:Excipients